Immunization of macaques with live simian human immunodeficiency virus (SHIV) vaccines conferred protection against AIDS induced by homologous and heterologous SHIVs and simian immunodeficiency virus

Anil Kumar, Sampa Mukherjee, Jing Shen, Shilpa J Buch, Zhuang Li, Istvan Adany, Zhenqian Liu, Wu Zhuge, Michael Piatak, Jeffrey D. Lifson, Harold M. McClure, Opendra Narayan

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

To evaluate the vaccine potential of SHIVs attenuated by deletion of viral accessory genes, seven rhesus macaques were sequentially immunized with ΔvpuΔnef SHIV-4 (vaccine-I) followed by ΔvpuSHIVPPC (vaccine-II). Despite the absence of virological evidence of productive infection with the vaccine strains, based on analysis of infectivity among peripheral blood mononuclear cells (PBMC) of the vaccinated animals, all seven animals developed binding as well as neutralizing antibodies against both vaccine-I and -II. The animals also developed vaccine virus-specific CTLs that recognized homologous as well as heterologous pathogenic SHIVs and SIV, and also soluble inhibitory factors that blocked the in vitro replication of the vaccine strains and different challenge viruses. Virus-specific cellular and humoral responses were sustained throughout a 58-week prechallenge period. To model aspects of natural transmission, the animals received a mucosal (rectal) challenge, with a mixture of three challenge viruses, SHIVKU, SHIV89.6P, and SIVmacR71/17E. Two mock-vaccinated control animals) inoculated with the same mixture of challenge viruses developed large numbers of infectious PBMC, high plasma viremia, and precipitous loss of CD4+ T cells. The control animals did not develop any immune responses and succumbed to AIDS between 6 and 7 weeks postchallenge. All seven vaccinated animals became infected with challenge viruses as indicated by the presence of infectious cells in the PBMC and/or viral RNA in plasma. However, peak plasma viremia in vaccinates was two to nearly five logs lower than in the control animals and later plasma viral RNA became undetectable in all vaccinates. Vaccinated animals maintained normal CD4+ T cell levels throughout the study. Challenge with pathogenic viruses caused massive anamnestic responses as determined by quantitation of virus-specific CD4+ and CD8+ T cells by intracellular IFN-γ staining, and these cells persisted for at least 74 weeks. The study is still in progress and at this time DNA of SIV has become undetectable in lymph nodes of six of the seven vaccinates, SHIV89.6P in five of the seven, and SHIVKU in three of the seven animals.

Original languageEnglish (US)
Pages (from-to)189-205
Number of pages17
JournalVirology
Volume301
Issue number2
DOIs
StatePublished - Jan 1 2002

Fingerprint

Simian Immunodeficiency Virus
Macaca
Immunization
Acquired Immunodeficiency Syndrome
Vaccines
HIV
Viruses
Blood Cells
Viremia
Viral RNA
T-Lymphocytes
X-Linked Combined Immunodeficiency Diseases
Viral Genes
Neutralizing Antibodies
Macaca mulatta
Lymph Nodes
Staining and Labeling

ASJC Scopus subject areas

  • Virology

Cite this

Immunization of macaques with live simian human immunodeficiency virus (SHIV) vaccines conferred protection against AIDS induced by homologous and heterologous SHIVs and simian immunodeficiency virus. / Kumar, Anil; Mukherjee, Sampa; Shen, Jing; Buch, Shilpa J; Li, Zhuang; Adany, Istvan; Liu, Zhenqian; Zhuge, Wu; Piatak, Michael; Lifson, Jeffrey D.; McClure, Harold M.; Narayan, Opendra.

In: Virology, Vol. 301, No. 2, 01.01.2002, p. 189-205.

Research output: Contribution to journalArticle

Kumar, Anil ; Mukherjee, Sampa ; Shen, Jing ; Buch, Shilpa J ; Li, Zhuang ; Adany, Istvan ; Liu, Zhenqian ; Zhuge, Wu ; Piatak, Michael ; Lifson, Jeffrey D. ; McClure, Harold M. ; Narayan, Opendra. / Immunization of macaques with live simian human immunodeficiency virus (SHIV) vaccines conferred protection against AIDS induced by homologous and heterologous SHIVs and simian immunodeficiency virus. In: Virology. 2002 ; Vol. 301, No. 2. pp. 189-205.
@article{5967f4bed73a4cccb208c961cc60adf5,
title = "Immunization of macaques with live simian human immunodeficiency virus (SHIV) vaccines conferred protection against AIDS induced by homologous and heterologous SHIVs and simian immunodeficiency virus",
abstract = "To evaluate the vaccine potential of SHIVs attenuated by deletion of viral accessory genes, seven rhesus macaques were sequentially immunized with ΔvpuΔnef SHIV-4 (vaccine-I) followed by ΔvpuSHIVPPC (vaccine-II). Despite the absence of virological evidence of productive infection with the vaccine strains, based on analysis of infectivity among peripheral blood mononuclear cells (PBMC) of the vaccinated animals, all seven animals developed binding as well as neutralizing antibodies against both vaccine-I and -II. The animals also developed vaccine virus-specific CTLs that recognized homologous as well as heterologous pathogenic SHIVs and SIV, and also soluble inhibitory factors that blocked the in vitro replication of the vaccine strains and different challenge viruses. Virus-specific cellular and humoral responses were sustained throughout a 58-week prechallenge period. To model aspects of natural transmission, the animals received a mucosal (rectal) challenge, with a mixture of three challenge viruses, SHIVKU, SHIV89.6P, and SIVmacR71/17E. Two mock-vaccinated control animals) inoculated with the same mixture of challenge viruses developed large numbers of infectious PBMC, high plasma viremia, and precipitous loss of CD4+ T cells. The control animals did not develop any immune responses and succumbed to AIDS between 6 and 7 weeks postchallenge. All seven vaccinated animals became infected with challenge viruses as indicated by the presence of infectious cells in the PBMC and/or viral RNA in plasma. However, peak plasma viremia in vaccinates was two to nearly five logs lower than in the control animals and later plasma viral RNA became undetectable in all vaccinates. Vaccinated animals maintained normal CD4+ T cell levels throughout the study. Challenge with pathogenic viruses caused massive anamnestic responses as determined by quantitation of virus-specific CD4+ and CD8+ T cells by intracellular IFN-γ staining, and these cells persisted for at least 74 weeks. The study is still in progress and at this time DNA of SIV has become undetectable in lymph nodes of six of the seven vaccinates, SHIV89.6P in five of the seven, and SHIVKU in three of the seven animals.",
author = "Anil Kumar and Sampa Mukherjee and Jing Shen and Buch, {Shilpa J} and Zhuang Li and Istvan Adany and Zhenqian Liu and Wu Zhuge and Michael Piatak and Lifson, {Jeffrey D.} and McClure, {Harold M.} and Opendra Narayan",
year = "2002",
month = "1",
day = "1",
doi = "10.1006/viro.2002.1544",
language = "English (US)",
volume = "301",
pages = "189--205",
journal = "Virology",
issn = "0042-6822",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Immunization of macaques with live simian human immunodeficiency virus (SHIV) vaccines conferred protection against AIDS induced by homologous and heterologous SHIVs and simian immunodeficiency virus

AU - Kumar, Anil

AU - Mukherjee, Sampa

AU - Shen, Jing

AU - Buch, Shilpa J

AU - Li, Zhuang

AU - Adany, Istvan

AU - Liu, Zhenqian

AU - Zhuge, Wu

AU - Piatak, Michael

AU - Lifson, Jeffrey D.

AU - McClure, Harold M.

AU - Narayan, Opendra

PY - 2002/1/1

Y1 - 2002/1/1

N2 - To evaluate the vaccine potential of SHIVs attenuated by deletion of viral accessory genes, seven rhesus macaques were sequentially immunized with ΔvpuΔnef SHIV-4 (vaccine-I) followed by ΔvpuSHIVPPC (vaccine-II). Despite the absence of virological evidence of productive infection with the vaccine strains, based on analysis of infectivity among peripheral blood mononuclear cells (PBMC) of the vaccinated animals, all seven animals developed binding as well as neutralizing antibodies against both vaccine-I and -II. The animals also developed vaccine virus-specific CTLs that recognized homologous as well as heterologous pathogenic SHIVs and SIV, and also soluble inhibitory factors that blocked the in vitro replication of the vaccine strains and different challenge viruses. Virus-specific cellular and humoral responses were sustained throughout a 58-week prechallenge period. To model aspects of natural transmission, the animals received a mucosal (rectal) challenge, with a mixture of three challenge viruses, SHIVKU, SHIV89.6P, and SIVmacR71/17E. Two mock-vaccinated control animals) inoculated with the same mixture of challenge viruses developed large numbers of infectious PBMC, high plasma viremia, and precipitous loss of CD4+ T cells. The control animals did not develop any immune responses and succumbed to AIDS between 6 and 7 weeks postchallenge. All seven vaccinated animals became infected with challenge viruses as indicated by the presence of infectious cells in the PBMC and/or viral RNA in plasma. However, peak plasma viremia in vaccinates was two to nearly five logs lower than in the control animals and later plasma viral RNA became undetectable in all vaccinates. Vaccinated animals maintained normal CD4+ T cell levels throughout the study. Challenge with pathogenic viruses caused massive anamnestic responses as determined by quantitation of virus-specific CD4+ and CD8+ T cells by intracellular IFN-γ staining, and these cells persisted for at least 74 weeks. The study is still in progress and at this time DNA of SIV has become undetectable in lymph nodes of six of the seven vaccinates, SHIV89.6P in five of the seven, and SHIVKU in three of the seven animals.

AB - To evaluate the vaccine potential of SHIVs attenuated by deletion of viral accessory genes, seven rhesus macaques were sequentially immunized with ΔvpuΔnef SHIV-4 (vaccine-I) followed by ΔvpuSHIVPPC (vaccine-II). Despite the absence of virological evidence of productive infection with the vaccine strains, based on analysis of infectivity among peripheral blood mononuclear cells (PBMC) of the vaccinated animals, all seven animals developed binding as well as neutralizing antibodies against both vaccine-I and -II. The animals also developed vaccine virus-specific CTLs that recognized homologous as well as heterologous pathogenic SHIVs and SIV, and also soluble inhibitory factors that blocked the in vitro replication of the vaccine strains and different challenge viruses. Virus-specific cellular and humoral responses were sustained throughout a 58-week prechallenge period. To model aspects of natural transmission, the animals received a mucosal (rectal) challenge, with a mixture of three challenge viruses, SHIVKU, SHIV89.6P, and SIVmacR71/17E. Two mock-vaccinated control animals) inoculated with the same mixture of challenge viruses developed large numbers of infectious PBMC, high plasma viremia, and precipitous loss of CD4+ T cells. The control animals did not develop any immune responses and succumbed to AIDS between 6 and 7 weeks postchallenge. All seven vaccinated animals became infected with challenge viruses as indicated by the presence of infectious cells in the PBMC and/or viral RNA in plasma. However, peak plasma viremia in vaccinates was two to nearly five logs lower than in the control animals and later plasma viral RNA became undetectable in all vaccinates. Vaccinated animals maintained normal CD4+ T cell levels throughout the study. Challenge with pathogenic viruses caused massive anamnestic responses as determined by quantitation of virus-specific CD4+ and CD8+ T cells by intracellular IFN-γ staining, and these cells persisted for at least 74 weeks. The study is still in progress and at this time DNA of SIV has become undetectable in lymph nodes of six of the seven vaccinates, SHIV89.6P in five of the seven, and SHIVKU in three of the seven animals.

UR - http://www.scopus.com/inward/record.url?scp=0036398415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036398415&partnerID=8YFLogxK

U2 - 10.1006/viro.2002.1544

DO - 10.1006/viro.2002.1544

M3 - Article

VL - 301

SP - 189

EP - 205

JO - Virology

JF - Virology

SN - 0042-6822

IS - 2

ER -